Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1976 2
1977 8
1978 8
1979 14
1980 18
1981 17
1982 26
1983 24
1984 27
1985 31
1986 22
1987 23
1988 43
1989 34
1990 49
1991 56
1992 53
1993 47
1994 53
1995 48
1996 54
1997 44
1998 46
1999 50
2000 63
2001 38
2002 44
2003 59
2004 65
2005 53
2006 71
2007 73
2008 49
2009 52
2010 63
2011 59
2012 50
2013 47
2014 56
2015 47
2016 60
2017 54
2018 51
2019 41
2020 50
2021 53
2022 51
2023 40
2024 22

Text availability

Article attribute

Article type

Publication date

Search Results

1,984 results

Results by year

Filters applied: . Clear all
Page 1
Pharmacokinetics of sodium valproate in dog and mouse.
Löscher W, Esenwein H. Löscher W, et al. Arzneimittelforschung. 1978;28(5):782-7. Arzneimittelforschung. 1978. PMID: 373773
The pharmacokinetics of sodium di-n-propyl-acetate (sodium valproate, Ergenyl) after i.v. and oral administration in dogs and mice were studied. After i.v. administration of 20 and 40 mg/kg sodium valproate in dogs a biphasic exponential …
The pharmacokinetics of sodium di-n-propyl-acetate (sodium valproate, Ergenyl) after i.v. and oral administratio …
An update on sodium valproate.
Rimmer EM, Richens A. Rimmer EM, et al. Pharmacotherapy. 1985 May-Jun;5(3):171-84. doi: 10.1002/j.1875-9114.1985.tb03413.x. Pharmacotherapy. 1985. PMID: 3927267 Review.
Sodium valproate has been in clinical use for the treatment of epilepsy in Great Britain since 1973 and in the United States since 1978. ...The role of therapeutic drug monitoring in the management of patients taking sodium valproate is controversial.. …
Sodium valproate has been in clinical use for the treatment of epilepsy in Great Britain since 1973 and in the United States s …
Teratogenicity of sodium valproate.
Alsdorf R, Wyszynski DF. Alsdorf R, et al. Expert Opin Drug Saf. 2005 Mar;4(2):345-53. doi: 10.1517/14740338.4.2.345. Expert Opin Drug Saf. 2005. PMID: 15794725 Review.
The teratogenicity of the widely popular antiepileptic drug (AED) and mood stabiliser sodium valproate (also known as valproate, VPA) has been evidenced by previous research; however, these findings have often been limited by a small population sample of expo …
The teratogenicity of the widely popular antiepileptic drug (AED) and mood stabiliser sodium valproate (also known as valpr …
Pharmacokinetics, drug interactions, and tolerability of valproate.
DeVane CL. DeVane CL. Psychopharmacol Bull. 2003;37 Suppl 2:25-42. Psychopharmacol Bull. 2003. PMID: 14624231 Review.
Valproate is a branched-chain carboxylic acid with an extensive history of use as an antiepileptic drug. ...This review summarizes valproate's pharmacokinetics, drug interactions, and tolerability as an aid to promote individualized pharmacotherapy. .. …
Valproate is a branched-chain carboxylic acid with an extensive history of use as an antiepileptic drug. ...This review summar …
Pharmacokinetics of valproate in pregnancy: mother-foetus-newborn.
Johannessen SI. Johannessen SI. Pharm Weekbl Sci. 1992 Jun 19;14(3A):114-7. doi: 10.1007/BF01962699. Pharm Weekbl Sci. 1992. PMID: 1502009 Review.
However, dose reduction after delivery may be necessary to avoid toxicity. Valproate and its metabolites undergo placental transfer. In the foetus the plasma level of valproate and the protein binding are higher than in maternal plasma, and the half-life of valpr …
However, dose reduction after delivery may be necessary to avoid toxicity. Valproate and its metabolites undergo placental transfer. …
The lack of effect of sodium valproate on the pharmacokinetics of oral contraceptive steroids.
Crawford P, Chadwick D, Cleland P, Tjia J, Cowie A, Back DJ, Orme ML. Crawford P, et al. Contraception. 1986 Jan;33(1):23-9. doi: 10.1016/0010-7824(86)90028-4. Contraception. 1986. PMID: 3082590
Prior to sodium valproate therapy the mean AUC for EE2 was 880 +/- 109 pg/ml X h (+/- S.E.) and for levonorgestrel it was 29.1 +/- 2.9 ng/ml X h (n = 4). ...We conclude that sodium valproate in the dose used (200 mg b.d.) does not interact with oral co …
Prior to sodium valproate therapy the mean AUC for EE2 was 880 +/- 109 pg/ml X h (+/- S.E.) and for levonorgestrel it was 29.1 …
Pharmacokinetics of slow-release preparations of sodium valproate.
Yamatogi Y, Yoshinaga H, Oka E, Ohtahara S, Yamashita S, Furuno K, Gomita Y. Yamatogi Y, et al. Psychiatry Clin Neurosci. 1995 Dec;49(5-6):309-10. doi: 10.1111/j.1440-1819.1995.tb01910.x. Psychiatry Clin Neurosci. 1995. PMID: 8726120 No abstract available.
1,984 results